CD274 and neoplasm: The low response rate of PD-1/PD-L1 immunotherapy in patients with CC may be due to the body's self-resistance to PD-1/PD-L1 inhibitors [9], including the loss of new tumor antigens in mismatch repair function, T cell dysfunction caused by T cell exhaustion, and the immunosuppressive components in TME [33, 34].